A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis

BACKGROUND: Tofacitinib (CP-690,550) is a novel Janus kinase inhibitor in development as an oral formulation for the treatment of several inflammatory diseases including psoriasis. OBJECTIVES: This phase 2a study aimed to assess the efficacy, systemic safety, local tolerability and systemic pharmaco...

Descripción completa

Detalles Bibliográficos
Autores principales: Ports, WC, Khan, S, Lan, S, Lamba, M, Bolduc, C, Bissonnette, R, Papp, K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2013
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3761190/
https://www.ncbi.nlm.nih.gov/pubmed/23387374
http://dx.doi.org/10.1111/bjd.12266

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3761190/
https://www.ncbi.nlm.nih.gov/pubmed/23387374
http://dx.doi.org/10.1111/bjd.12266

Ejemplares similares